Actinium Pharmaceuticals Inc (ATNM)

$1.25 -0.01 (-0.79%)
Market Cap 34.51M
Revenue (ttm) 90,000.00
Net Income (ttm) -33.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37,655.55%
Debt to Equity Ratio 0.00
Volume 130,072
Avg Vol 137,056
Day's Range N/A - N/A
Shares Out 31.38M
Stochastic %K 90%
Beta -0.21
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
greencheese500
greencheese500 Apr. 16 at 9:18 PM
$ATNM Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa https://share.google/J9QKlFxgNkLg5D4te If my guess is correct, then they are announcing the phase1 updates (South Africa and Australia) in the upcoming AACR meeting.
0 · Reply
gooddoggie
gooddoggie Apr. 16 at 8:50 PM
$ATNM Down today. Probably bankruptcy coming. I wonder why it’s even worth getting up in the morning.
1 · Reply
johnny4cures
johnny4cures Apr. 16 at 7:47 PM
$ATNM Looking forward to the data whatever it is!!!
0 · Reply
xlinkx
xlinkx Apr. 16 at 5:18 PM
$ATNM No iND application required in human drug trials in Australia and South Africa. This should speed things up considerably for ATNM-400. I hope the company PRs shareholders when they start.
1 · Reply
Pinto72
Pinto72 Apr. 16 at 4:34 PM
$ATNM What happened @johnny4skin? 🤣🤣🤣🤣🤣
0 · Reply
Pinto72
Pinto72 Apr. 16 at 2:30 PM
$ATNM BANKRUPTCY = AS SOON eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣
0 · Reply
mauryrosen
mauryrosen Apr. 16 at 2:21 PM
$ATNM Here we go! This goes up 15 cents and it starts the posts that we are thiiiissss close to being millionaires. Watched this same scenario hundreds of times over the past 10 years, only this time I’m Prepared!! …… got my popcorn, raisonettes, and drink. It’s going to be Tough, but I will try very hard NOT to keep my enthusiasm about becoming a millionaire to an extreme.
2 · Reply
xlinkx
xlinkx Apr. 16 at 1:53 PM
$ATNM
0 · Reply
dm4
dm4 Apr. 16 at 1:41 PM
$ATNM
0 · Reply
greencheese500
greencheese500 Apr. 16 at 1:28 PM
$ATNM AACR meeting next week on Tuesday. Get Loaded and hold for next 6 months. A big acquisition is in next line !
0 · Reply
Latest News on ATNM
NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Apr 15, 2026, 8:00 AM EDT - 1 day ago

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Apr 6, 2026, 7:30 AM EDT - 10 days ago

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Feb 17, 2026, 8:00 AM EST - 2 months ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Dec 12, 2025, 8:45 AM EST - 4 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec 1, 2025, 8:45 AM EST - 4 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov 17, 2025, 8:30 AM EST - 5 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 6 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 6 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 6 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 9 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 10 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 1 year ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 1 year ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 1 year ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 1 year ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

greencheese500
greencheese500 Apr. 16 at 9:18 PM
$ATNM Actinium Pharmaceuticals Advances ATNM-400 B7-H3 Candidate Into Phase 1 Clinical Trial in South Africa https://share.google/J9QKlFxgNkLg5D4te If my guess is correct, then they are announcing the phase1 updates (South Africa and Australia) in the upcoming AACR meeting.
0 · Reply
gooddoggie
gooddoggie Apr. 16 at 8:50 PM
$ATNM Down today. Probably bankruptcy coming. I wonder why it’s even worth getting up in the morning.
1 · Reply
johnny4cures
johnny4cures Apr. 16 at 7:47 PM
$ATNM Looking forward to the data whatever it is!!!
0 · Reply
xlinkx
xlinkx Apr. 16 at 5:18 PM
$ATNM No iND application required in human drug trials in Australia and South Africa. This should speed things up considerably for ATNM-400. I hope the company PRs shareholders when they start.
1 · Reply
Pinto72
Pinto72 Apr. 16 at 4:34 PM
$ATNM What happened @johnny4skin? 🤣🤣🤣🤣🤣
0 · Reply
Pinto72
Pinto72 Apr. 16 at 2:30 PM
$ATNM BANKRUPTCY = AS SOON eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣
0 · Reply
mauryrosen
mauryrosen Apr. 16 at 2:21 PM
$ATNM Here we go! This goes up 15 cents and it starts the posts that we are thiiiissss close to being millionaires. Watched this same scenario hundreds of times over the past 10 years, only this time I’m Prepared!! …… got my popcorn, raisonettes, and drink. It’s going to be Tough, but I will try very hard NOT to keep my enthusiasm about becoming a millionaire to an extreme.
2 · Reply
xlinkx
xlinkx Apr. 16 at 1:53 PM
$ATNM
0 · Reply
dm4
dm4 Apr. 16 at 1:41 PM
$ATNM
0 · Reply
greencheese500
greencheese500 Apr. 16 at 1:28 PM
$ATNM AACR meeting next week on Tuesday. Get Loaded and hold for next 6 months. A big acquisition is in next line !
0 · Reply
gooddoggie
gooddoggie Apr. 16 at 12:53 PM
$ATNM $10 AS SOON!!!
0 · Reply
Invest2live
Invest2live Apr. 16 at 12:37 PM
$ATNM this has potential; do your DD and get in.
0 · Reply
greencheese500
greencheese500 Apr. 16 at 1:02 AM
$ATNM 759,562 volume today 😇 Big day is coming 🙏
0 · Reply
noggindog
noggindog Apr. 15 at 9:39 PM
$ATNM Big gain today AND some volume. Love it!
0 · Reply
janlukas
janlukas Apr. 15 at 8:47 PM
$ATNM There will be a crazy rush above $100 after years of accumulation. A globally revolutionary product.
0 · Reply
Pinto72
Pinto72 Apr. 15 at 8:43 PM
$ATNM ToOtS oUr LoDiNg🚀🚀🚀🚀 ByEiNg WiT bOtE hAnDz🚀🚀🚀🚀🚀 HELLOOOOOOO RICHIII!!!!!! PUMP & DUMP🚀🚀🚀🚀🚀 BANKRUPTCY = AS SOON🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Xarevira
Xarevira Apr. 15 at 8:01 PM
$ATNM 4x the average daily volume traded in one hour. Interesting…
0 · Reply
johnny4cures
johnny4cures Apr. 15 at 7:27 PM
$ATNM Some kind of recovery in the making and huge volume makes it the real deal.
0 · Reply
thagreatbul
thagreatbul Apr. 15 at 7:09 PM
$ATNM Very happy with another 10% profit. Waiting for the upcoming dilution before re entry.
0 · Reply
xlinkx
xlinkx Apr. 15 at 6:27 PM
$ATNM ATNM should be very close to human dosing in the ATNM-400 trial being conducted in South Africa and Australia. These trials were set up starting in December of last year. This will be good news for investors. Maybe we get some news on this in the near future.
1 · Reply
Pinto72
Pinto72 Apr. 15 at 4:33 PM
$ATNM bYe OwT kUmInG🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!🤣🤣🤣🤣🤣
0 · Reply
greencheese500
greencheese500 Apr. 15 at 4:16 PM
$ATNM Buyout is coming. Day Traders ! This is the big opportunity. Don't lose it !
3 · Reply